The Ethical Frontiers of Brain-Computer Interfaces
The challenge is not just to minimize harm, but to make choices that expand human flourishing rather than reduce us to more efficient workers or more predictable consumers.
Cyril Eleftheriou</a> is the neurotech lead at <a href=https://medcitynews.com/author/celeftheriou/"https://subsense-bci.com/">Subsense, leading R&D in visual neuroscience, interface biology, and precision imaging for the company’s non-surgical, nanoparticle-based brain-computer interface. Formerly a Principal Scientist at Novartis, he brings over 15 years of experience spanning the U.K., Italy, and the U.S. in neuro-electronic interfacing, advanced imaging, and retinal regeneration. His research has ranged from gene therapy and nanoparticle biologics to multiphoton microscopy and neural circuit mapping. At Subsense, Cyril applies his multidisciplinary expertise to advance seamless mind-machine communication and redefine how humans interact with technology through safe, scalable, non-invasive neural interfaces." />
The challenge is not just to minimize harm, but to make choices that expand human flourishing rather than reduce us to more efficient workers or more predictable consumers.